Akash Tewari Analyst PerformanceGlobal Head of Biopharmaceutical Research at Jefferies Financial GroupAkash Tewari is a stock analyst at Jefferies Financial Group focused in the healthcare sector, covering 24 publicly traded companies. Over the past year, Akash Tewari has issued 32 stock ratings, including buy and hold recommendations. While full access to Akash Tewari's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Akash Tewari's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access to unlock analyst rankings MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings48 Last 4 YearsBuy Recommendations84.09% 37 Buy RatingsCompanies Covered24 Unique Companies Ratings Distribution44RatingsDistribution of strong buy, buy, hold, and sell ratings by Akash Tewari.RatingPercentageCount Strong Buy0.0%0 ratings Buy84.1%37 ratings Hold13.6%6 ratings Sell2.3%1 ratingsOut of 44 total stock ratings issued by Akash Tewari at Jefferies Financial Group, the majority (84.1%) have been Buy recommendations, followed by 13.6% Hold and 2.3% Sell.Best & Worst CallsBest Call000.0%ALKSOct 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call00.0%EXELMay 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ87.5% of companies on NASDAQ21 companiesNYSE12.5% of companies on NYSE3 companiesAkash Tewari, an analyst at Jefferies Financial Group, currently covers 24 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare21 companies87.5%Miscellaneous3 companies12.5%Akash Tewari of Jefferies Financial Group specializes in stock coverage within the Healthcare sector, with additional focus on companies.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY16 companies66.7%PHARMACEUTICALS5 companies20.8%Miscellaneous3 companies12.5% Akash Tewari's Ratings History at Jefferies Financial Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter More filters Fewer filters Done 0 Results Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsLQDALiquidia11/10/2026Boost Price Target$51.40$62.00Buy$0.0000.00% ROIIAMIambic Therapeutics11/10/2026Initiated Coverage$13.38$35.00Buy$0.0000.00% ROILLYEli Lilly and Company11/9/2026Boost Price Target$1,413.22$1,700.00Buy$0.0000.00% ROIGILDGilead Sciences11/4/2026Set Price Target$167.47$196.00$0.0000.00% ROIGILDGilead Sciences10/23/2026Reiterated Rating$157.19$185.00Buy$0.0000.00% ROIETRAElectra Therapeutics10/13/2026Initiated Coverage$9.32$32.00Buy$0.0000.00% ROIETRAElectra Therapeutics10/13/2026Initiated Coverage$8.61$32.00Buy$0.0000.00% ROIBMYBristol Myers Squibb10/12/2026Reiterated Rating$57.64$76.00Buy$0.0000.00% ROIREGNRegeneron Pharmaceuticals10/1/2026Boost Price Target$741.89$930.00Buy$0.0000.00% ROIAMGNAmgen9/23/2026Reiterated Rating$410.24$410.00Hold$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. LTGOLatigo Biotherapeutics9/1/2026Initiated Coverage$22.02$50.00Buy$0.0000.00% ROILTGOLatigo Biotherapeutics9/1/2026Initiated Coverage$22.26$50.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical8/31/2026Boost Price Target$65.78$105.00Buy$0.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock7/27/2026Initiated Coverage$28.82$50.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals7/9/2026Lower Price Target$64.51$90.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals7/9/2026Lower Price Target$64.32$90.00Buy$0.0000.00% ROIAPGEApogee Therapeutics6/24/2026Downgrade$132.98$135.00Hold$0.0000.00% ROILLYEli Lilly and Company6/9/2026Boost Price Target$1,142.22$1,350.00Buy$0.0000.00% ROIBNTXBioNTech6/1/2026Reiterated Rating$92.55Buy$0.0000.00% ROILLYEli Lilly and Company5/21/2026Boost Price Target$1,056.87$1,330.00$0.0000.00% ROISYRESpyre Therapeutics4/13/2026Boost Price Target$64.08$85.00Buy$0.0000.00% ROIBNTXBioNTech3/25/2026Reiterated Rating$86.81Buy$0.0000.00% ROILLYEli Lilly and Company3/13/2026Set Price Target$998.85$1,300.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical3/12/2026Reiterated Rating$60.12$103.00Buy$0.0000.00% ROIAMGNAmgen3/10/2026Initiated Coverage$376.97$350.00Hold$0.0000.00% ROIGILDGilead Sciences3/10/2026Initiated Coverage$146.63$180.00Buy$0.0000.00% ROIVRTXVertex Pharmaceuticals3/10/2026Initiated Coverage$460.87$580.00Buy$0.0000.00% ROIBNTXBioNTech3/10/2026Lower Price Target$84.09$138.00Buy$0.0000.00% ROIAPGEApogee Therapeutics2/2/2026Reiterated Rating$66.06$95.00Buy$0.0000.00% ROICYTKCytokinetics1/9/2026Reiterated Rating$64.41$90.00Buy$0.0000.00% ROITERNTerns Pharmaceuticals12/10/2025Reiterated Rating$44.81$70.00Buy$0.0000.00% ROIBNTXBioNTech12/3/2025Reiterated Rating$96.78$151.00Buy$0.0000.00% ROITERNTerns Pharmaceuticals11/3/2025Boost Price Target$14.03$35.00Buy$0.0000.00% ROIALKSAlkermes10/28/2025Set Price Target$30.97$56.00Buy$00.0000.00% ROIBMRNBioMarin Pharmaceutical10/28/2025Reiterated Rating$52.67Outperform$00.0000.00% ROIENTAEnanta Pharmaceuticals10/1/2025Upgrade$10.93$20.00Buy$00.0000.00% ROIIONSIonis Pharmaceuticals9/2/2025Boost Price Target$57.43$96.00Buy$00.0000.00% ROIREGNRegeneron Pharmaceuticals8/27/2025Boost Price Target$587.65$831.00Buy$000.0000.00% ROICBIOCrescent Biopharma8/25/2025Initiated Coverage$15.06$26.00Buy$00.0000.00% ROIBMRNBioMarin Pharmaceutical7/15/2025Set Price Target$58.23$95.00Outperform$00.0000.00% ROI432 miles southeast of Washington, DC… (Ad)Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip maker for nearly four decades, including AMD, Intel, NVIDIA, Samsung and Taiwan Semiconductor. Washington is set to declare it a national strategic resource and ban its export. Apple, NVIDIA and Amazon have committed over $2 trillion, and Morgan Stanley estimates a $10 trillion economic boom. One small U.S. mining company sits at the center of it.Get the full report and the ticker of the U.S. company behind it.ARVNArvinas5/2/2025Reiterated Rating$7.23$10.00Hold$00.0000.00% ROIBMYBristol Myers Squibb4/23/2025Lower Price Target$49.82$68.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupTD CowenTruist FinancialPiper SandlerBMO Capital MarketsRaymond James FinancialMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.